Advanced Cancer Clinical Trial
Official title:
Patient and Family Decision Making and Information Disclosure Preferences in the Palliative Care Setting: a Multi-Center Survey in Chile, Guatemala, and U.S.
The goal of this research study is to learn about any differences in certain health-related
preferences between patients with cancer and their families.
The main preferences being studied are how decisions are made about healthcare, as well as
how much information people want to know about cancer.
Specifically, researchers will compare questionnaire and interview data from
Hispanic-Americans living in the United States (the M. D. Anderson part of this multicenter
study) with Hispanics living in Latin America (in particular, Argentina, Chile, and
Guatemala).
Study Background:
People from different cultures may have different preferences in the way decisions about
their healthcare are made, as well as how much information they may want to know about the
diseases they may have. However, patients and families sometimes disagree about these
preferences. In this study, researchers want to learn about any differences in healthcare
decision-making and information-sharing preferences between patients and their families,
among a group of people from different Hispanic backgrounds.
(Please note that the phrase "family member" has been used in this consent form for short,
but the definition includes non-family members that you may consider a "significant other").
Screening Procedures:
Participants in this study must also agree to give the name of a family member (a parent,
spouse, adult child, sibling, other family member, or a non-family member that you consider
a "significant other") that researchers can ask to participate in a separate part of this
study that will require signing a separate consent form. (If the person of your choice is
not with you at the time of joining the study, he/she may come back to the clinic at your
next follow-up visit.)
If the family member agrees, he/she will complete a similar series of questionnaires about
his/her preferences in decisions about your healthcare, what information he/she might want
you to know about the disease, and what information he/she might want to know about the
disease him/herself. Like you, he/she will also be asked how decisions about your healthcare
have been made, his/her satisfaction with those decisions and your healthcare, and his/her
sense of connection with what he/she defines to be the overall Hispanic culture. He/she will
also complete a similar interview on general information (such as marital status and
educational level).
Study Visit:
If you agree to take part in this study and you have given the name of a family member, you
will be interviewed to ask for general information about yourself ("demographic" information
such as marital status and educational level).
After that, you will complete a series of questionnaires that ask about your preferences in
decisions about your healthcare and what information you may want to know about the disease,
how decisions about your healthcare have been made, your satisfaction with those decisions
and your healthcare, and your sense of connection with what you define to be the overall
Hispanic culture.
It should take about 5-10 minutes for the interview and another 20-30 minutes to complete
the questionnaires.
Your interview and questionnaire responses will not be shared with your regular doctor. If
you feel you need a doctor's opinion about anything that is asked about in the interview
and/or questionnaires, please contact your doctor.
Family Member's Participation:
Your family member would complete the questionnaires separately and be interviewed
separately from you. You may ask as many additional family members as needed, until one
agrees. However, if the family member is scheduled for his/her study visit but does not end
up completing the study procedures (interview and questionnaires), your interview and
questionnaire data will be destroyed without being used in this study.
Confidentiality:
Your interview and questionnaire responses will only be used for this research study, and
will not be shared with your family member.
Length of Study Participation:
After completing the interview and questionnaires, your participation in this study will be
over.
This is an investigational study. In total, up to 900 patients and family members will take
part in this multicenter study. Up to 300 will be enrolled at M. D. Anderson.
;
Intervention Model: Single Group Assignment, Masking: Open Label
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03181854 -
Randomized Controlled Trial of Integrated Early Palliative Care
|
N/A | |
Completed |
NCT01197170 -
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
|
Phase 1 | |
Recruiting |
NCT05045040 -
Empathetic Communication Facilitation Program for Early Initiation of End-of-life Discussions
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03994601 -
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Completed |
NCT01393990 -
A Study of LY2228820 in Participants With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02857270 -
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT04121676 -
Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer
|
Phase 1 | |
Active, not recruiting |
NCT03177291 -
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
|
Phase 1 | |
Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 | |
Active, not recruiting |
NCT03674567 -
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
|
Phase 1/Phase 2 | |
Recruiting |
NCT04823377 -
Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.
|
N/A | |
Completed |
NCT02778126 -
A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02529553 -
A Study of LY3076226 in Participants With Advanced or Metastatic Cancer
|
Phase 1 | |
Completed |
NCT02507544 -
A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02245204 -
Phase I Studies of Chlorogenic Acid for Injection for Tolerance and Pharmacokinetic of Advanced Cancers
|
Phase 1 | |
Terminated |
NCT01929941 -
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
|
Phase 1 | |
Completed |
NCT01583777 -
Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer
|
Phase 1 |